Research ArticleOriginal Research

Barriers to Follow-Up Colonoscopy After Positive FIT or Multitarget Stool DNA Testing

Gregory S. Cooper, Ashley Grimes, James Werner, Shufen Cao, Pingfu Fu and Kurt C. Stange
The Journal of the American Board of Family Medicine January 2021, 34 (1) 61-69; DOI: https://doi.org/10.3122/jabfm.2021.01.200345

References

  1. 1.↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    . Cancer statistics, 2020. CA Cancer J Clin 2020;70:7–30.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Rex DK,
    2. Boland CR,
    3. Dominitz JA
    . Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multisociety Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112:1016–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bibbins-Domingo K,
    2. Grossman DC,
    3. Curry SJ,
    4. et al
    . Screening for colorectal cancer: US Preventive Services Task Force recommendation. JAMA 2016;315:2564–75.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Smith RA,
    2. Andrews KS,
    3. Brooks D,
    4. et al
    . Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019;69:184–210.
    OpenUrl
  5. 5.↵
    1. Robertson DJ,
    2. Imperiale TF
    . Stool testing for colorectal cancer screening. Gastroenterology 2015;149:1286–93.
    OpenUrl
  6. 6.↵
    1. Robertson DJ,
    2. Lee JK,
    3. Boland CR,
    4. et al
    . Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol 2017;112:37–53.
    OpenUrl
  7. 7.↵
    1. Tosteson ANA,
    2. Beaber EF,
    3. Tiro J,
    4. et al
    . Variation in screening abnormality rates and follow-up of breast, cervical and colorectal screening within the PROSPR Consortium. J Gen Intern Med 2016;31:372–9.
    OpenUrl
  8. 8.↵
    1. Etzioni DA,
    2. Yano EM,
    3. Rubinstein LV,
    4. et al
    . Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Col Rect 2006;49:1002–10.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. May FP,
    2. Yano EM,
    3. Provenzale D,
    4. et al
    . Barriers to colonoscopies for patients with positive results from fecal immunochemical tests during colorectal cancer screening. Clin Gastroenterol Hepatol 2019;17:469–76.
    OpenUrl
  10. 10.↵
    1. Fisher DA,
    2. Jeffreys A,
    3. Coffman CJ,
    4. Fasanella K
    . Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev 2006;15:1232–5.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Turner B,
    2. Myers RE,
    3. Hyslop T,
    4. et al
    . Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med 2003;18:357–63.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Prince M,
    2. Lester L,
    3. Chiniwala R,
    4. Berger B
    . Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients. World J Gastroenterol 2017;23:464–71.
    OpenUrl
  13. 13.↵
    1. Corley DA,
    2. Jensen CD,
    3. Quinn VP,
    4. et al
    . Association between time to colonoscopy after a positive fecal test result and risk of colorectal cancer and cancer stage at diagnosis. JAMA 2017;317:1631–41.
    OpenUrlCrossRef
  14. 14.↵
    1. Doubeni CA,
    2. Gabler NB,
    3. Wheeler CM,
    4. et al
    . Timely follow-up of positive cancer screening results: a systematic review and recommendations from the PROSPR consortium. CA Cancer J Clin 2018;68:199–216.
    OpenUrl
  15. 15.↵
    1. Meester RGS,
    2. Zauber AG,
    3. Doubeni CA,
    4. et al
    . Consequences of increasing time to colonoscopy examination after positive result from fecal colorectal cancer screening test. Clin Gastroenterol Hepatol 2016;14:1445–51.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Issaka RB,
    2. Singh MH,
    3. Oshima SM,
    4. et al
    . Inadequate utilization of diagnostic colonoscopy following abnormal FIT results in an integrated safety-net system. Am J Gastroenterol 2017;112:375–82.
    OpenUrl
  17. 17.↵
    1. Martin J,
    2. Halm EA,
    3. Tiro JA,
    4. et al
    . Reasons for lack of diagnostic colonoscopy after positive result on fecal immunochemical test in a safety-net health system. Am J Med 2017;130:93.e193–e197.
    OpenUrl
  18. 18.↵
    1. Llovet D,
    2. Serenity M,
    3. Conn LG,
    4. et al
    . Reasons for lack of follow-up colonoscopy among persons with a positive fecal occult blood test result: a qualitative study. Am J Gastroenterol 2018;113:1872–80.
    OpenUrl
  19. 19.↵
    1. Alsayid M,
    2. Singh MH,
    3. Issaka R,
    4. et al
    . Yield of colonoscopy after a positive result from a fecal immunochemical test OC-light. Clin Gastroenterol Hepatol 2018;16:1593–7.
    OpenUrl
  20. 20.↵
    1. Imperiale TF,
    2. Ransohoff DF,
    3. Itzkowitz SH,
    4. et al
    . Multitarget stool DNA testing for colorectal cancer screening. N Engl J Med 2014;370:1287–97.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Schneider JL,
    2. Rivelli JS,
    3. Gruss I,
    4. et al
    . Barriers and facilitators to timely colonoscopy completion for safety net clinic patients. Am J Health Behav 2020;44:460–72.
    OpenUrl
  22. 22.↵
    1. Selby K,
    2. Baumgartner C,
    3. Levin TR,
    4. et al
    . Interventions to improve follow-up on positive results on fecal blood tests: a systematic review. Ann Intern Med 2017;167:565–75.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Selby K,
    2. Jensen CD,
    3. Zhao WK,
    4. et al
    . Strategies to improve follow-up after positive fecal immunochemical tests in a community-based setting: a mixed-methods study. Clin Transl Gastroenterol 2019;10:e00010.
    OpenUrl
  24. 24.↵
    1. Gupta S,
    2. Coronado GD,
    3. Argenbright K,
    4. et al
    . Mailed fecal immunochemical test outreach for colorectal cancer screening: summary of a Centers for Disease Control and Prevention–sponsored summit. CA Cancer J Clin 2020;70:283–98.
    OpenUrl
  25. 25.↵
    1. DeGroff A,
    2. Gressard L,
    3. Glover-Kudon R,
    4. et al
    . Assessing the implementation of a patient navigation intervention for colonoscopy screening. BMC Health Serv Res 2019;19:803.
    OpenUrl
  26. 26.↵
    1. Rice K,
    2. Sharma K,
    3. Li C,
    4. et al
    . Cost-effectiveness of a patient navigation intervention to increase colonoscopy screening among low-income adults in New Hampshire. Cancer 2019;125:601–9.
    OpenUrl
  27. 27.↵
    1. Zapka J,
    2. Taplin SH,
    3. Price RA,
    4. et al
    . Factors in quality care—The case of follow-up to abnormal cancer screening tests—Problems in the steps and interfaces of care. J Natl Cancer Inst Monogr 2010;2010:58–71.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords